TrialCancer chemotherapy and pharmacology2017

Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.

Heinz-Josef Lenz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.